NCT06641908 - Anti-GD2 ADC M3554 in Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 8, 2024

Primary Completion Date

March 27, 2027

Study Completion Date

March 27, 2028

Conditions

Advanced Solid Tumor

Interventions

DRUG

M3554

M3554 will be administered at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended Dose is determined in participants with STS (dose escalation A) and glioblastoma and IDH wildtype (dose escalation B).

Trial Locations (9)

10022

WITHDRAWN

Memorial Sloan-Kettering Cancer Center (MSKCC) - New York - Memorial Sloan Kettering Cancer Center (CC)- Westc, New York

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

Unknown

RECRUITING

UZ Leuven, Leuven

RECRUITING

Institut Bergonié - Service d'Oncologie Médicale, Bordeaux

RECRUITING

Centre Oscar Lambret - cancerologie generale, Lille

NOT_YET_RECRUITING

Centre Leon Berard - Service d'Oncologie Medicale, Lyon

NOT_YET_RECRUITING

Centre Antoine Lacassagne - Service d'Hématologie Oncologie, Nice

RECRUITING

National Cancer Center Hospital, Chūōku

All Listed Sponsors

collaborator

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY

lead

EMD Serono Research & Development Institute, Inc.

INDUSTRY